Know Cancer

forgot password

Clinical and Basic Investigations Into Erdheim-Chester Disease

2 Years
80 Years
Open (Enrolling)
Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer

Thank you

Trial Information

Clinical and Basic Investigations Into Erdheim-Chester Disease

Erdheim-Chester Diseases (ECD) is a very rare non-Langerhans cell histiocytosis of unknown
origin and pathogenesis. It has been reported mainly in adult males over the age of 40
years, although cases have been reported in females as well. Children are rarely affected by
this condition. No causative gene has been identified; family studies have not been
performed due to the rarity and sporadic nature of the disease. The clinical characteristics
of ECD range from asymptomatic to multisystemic involvement; longitudinal progression and
natural history have not been well documented. ECD commonly affects the bones, kidneys,
retroperitoneal space, skin and brain. After diagnosis, the disease progresses rapidly,
causing fatal outcomes due to severe lung disease, chronic renal failure, cardiomyopathy and
other complications. The diagnosis of ECD relies upon imaging studies and specific
pathologic findings in biopsies of affected organs, i.e., fibrosis and infiltration of the
affected tissues with foamy histiocytes, lymphocytes, and plasma cells. Immunohistochemistry
reveals cells positive for CD68 and negative for CD1a and S-100. There is no standard
treatment for ECD, although chemotherapy, radiation, stem cell transplantion,
alpha-interferon, steroids and sirolimus have been proposed. Symptomatic improvement has
been reported with some of these therapies, but death within a few years after diagnosis
remains the expected outcome. In this protocol, we will clinically evaluate ECD patients,
obtain cells, plasma, and urine, search for genes that can be responsible for ECD, and
perform other studies dictated by each patient's presentation.

Inclusion Criteria


- ECD patients of any gender and ethnicity age 2-80 years

- Patients will be diagnosed as having ECD based upon pathologic evaluations of
affected organs.

- Family members are also invited to be part of the study. They will undergo a limited
evaluation at the NIH Clinical Center


- Patients will be excluded if they have a suspected diagnosis of ECD not confirmed by
biopsy or another form of histiocytosis or cannot travel to the NIH because of their
medical condition.

- Children under age two year are excluded because there is no urgency for a very early
diagnosis and care is more readily provided to older children at the Clinical Center.

- Pregnant women will not be able to be part of this study because of the risks that
can be harmful to the fetus.

Type of Study:


Study Design:


Principal Investigator

Juvianee I Estrada Veras, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Human Genome Research Institute (NHGRI)


United States: Federal Government

Study ID:




Start Date:

July 2011

Completion Date:

Related Keywords:

  • Myelofibrosis
  • Gaucher Disease
  • Pulmonary Fibrosis
  • Hermansky-Pudlak Syndrome (HPS)
  • Cancer
  • Histiocytosis
  • Xanthomatosis
  • Fibrosis
  • Osteosclerosis
  • Erdheim-Chester Disease
  • ECD
  • Primary Myelofibrosis
  • Fibrosis
  • Gaucher Disease
  • Pulmonary Fibrosis
  • Hermanski-Pudlak Syndrome
  • Erdheim-Chester Disease



National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892